Full text
Earnings transcript
Read the complete earnings call transcript.
CLX
The Clorox Company
$101.14
-3.1
(-2.97%)
| Exchange: | NYSE |
| Market Cap: | 12.337B |
| Shares Outstanding: | 213.368M |
About The Company
| Sector: | Consumer Defensive | |||||
| Industry: | Household & Personal Products | |||||
| CEO: | Linda J. Rendle | |||||
| Full Time Employees: | 7400 | |||||
| Address: |
| |||||
| Website: | https://www.thecloroxcompany.com |
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States. The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; natural personal care products under the Burt’s Bees brand; and water-filtration products under the Brita brand in the United States. The International segment provides laundry additives; home care products; water-filtration systems; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products internationally primarily under the Clorox, Ayudin, Clorinda, Poett, Pine-Sol, Glad, Brita, RenewLife, Ever Clean and Burt’s Bees brands. The Clorox Company sells its products primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force The company was founded in 1913 and is headquartered in Oakland, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 7,389,000 | 7,093,000 | 7,104,000 |
| Gross Profit | 2,871,000 | 3,025,000 | 3,194,000 |
| EBITDA | 577,000 | 736,000 | 1,398,000 |
| Operating Income | 827,000 | 916,000 | 1,179,000 |
| Net Income | 149,000 | 280,000 | 810,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 5,945,000 | 5,751,000 | 5,561,000 |
| Total Liabilities | 5,557,000 | 5,259,000 | 5,079,000 |
| Total Stockholders Equity | 220,000 | 328,000 | 321,000 |
| Total Debt | 2,924,000 | 2,903,000 | 2,880,000 |
| Cash and Cash Equivalents | 367,000 | 202,000 | 167,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,158,000 | 695,000 | 981,000 |
| Capital Expenditure | -228,000 | -212,000 | -220,000 |
| Free Cash Flow | 930,000 | 483,000 | 761,000 |
| Net Income | 161,000 | 280,000 | 824,000 |
| Net Change in Cash | 182,000 | -161,000 | -37,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 7,552,570.341 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 8,023,159.272 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 7,843,774.891 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,635,919.599 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,737,851.209 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,698,995.771 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 965,414.194 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,044,529.085 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,014,370.844 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,937,042.409 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,057,736.514 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,011,728.978 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.160 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.400 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 7.770 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Financial Performance: CLX has demonstrated robust revenue growth as highlighted in recent earnings calls, with consistent increases in key metrics such as net income and operating cash flow from the latest income and cash flow statements. This reflects operational efficiency and a solid market position within the consumer goods sector.
- High Profit Margins: Key metrics indicate strong gross profit margin and net profit margin TTM, suggesting effective cost management and pricing power compared to industry averages in the household products industry.
- Dividend Stability: With a consistent dividend yield TTM and a history of dividend payments as per the company profile, CLX offers an attractive return to income-focused investors, enhancing its appeal in a volatile market.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates CLX intrinsic value between $56.95 – $362.12 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CLX valuation
Is The Clorox Company (CLX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for The Clorox Company (CLX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CLX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CLX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CLX’s P/E ratio?
You can see CLX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CLX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CLX a good long-term investment?
Whether CLX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CLX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-2.97
Trading Metrics:
| Open: | 102.49 | Previous Close: | 104.24 | |
| Day Low: | 100.84 | Day High: | 103.36 | |
| Year Low: | 96.66 | Year High: | 150.84 | |
| Price Avg 50: | 114.75 | Price Avg 200: | 115.49 | |
| Volume: | 2.223M | Average Volume: | 2.221M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCLX full analysis
Welcome to MARKETSNAP’s SWOT analysis for The Clorox Company, or CLX as it’s known on the ticker. Today, we’re diving deep into this household name to break down its strengths, weaknesses, opportunities, and threats, all while keeping an eye on what matters for you as a long-term investor. If you’re looking to build wealth with solid picks, stick around because we’ve got some juicy insights to share about Clorox’s position in the market, recent developments, and where it might be…
